Biomarker changes after cancer treatment in thoracic and non-thoracic cancers
Official title: Characterising Circulating Biomarker Signatures From Diverse Cancer Treatment Modalities - A Pilot Study
Run by University Hospitals Coventry and Warwickshire NHS Trust · NCT07803289 · Data updated 2026-11-12
This study tests circulating biomarkers like miRNAs and proteins to see how they change after cancer therapy, comparing pre-treatment baselines and two patient groups: radical RT/chemo-RT and IO-based complex systemic therapy.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 48 (estimated) |
| Sponsor | University Hospitals Coventry and Warwickshire NHS Trust Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Coventry) |
| Status | Recruiting |
| Started | May 1, 2026 |
| Main results expected | October 31, 2027 |
| Study ends | April 30, 2028 |
| Registry record updated | September 3, 2026 |
| Trial ID | NCT07803289 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with solid tumors scheduled for first-line radical RT/chemo-RT (cohort 1) or IO-based complex systemic therapy (cohort 2).
✕Probably not a fit
Patients not showing biomarker changes or those outside first-line treatment may not receive direct benefits.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to identify changes in miRNA and protein biomarkers before and after cancer treatment, and to compare these changes between patients receiving radical RT/chemo-RT and those receiving IO-based complex systemic therapy. It will examine links between dysregulated miRNAs, immune/inflammatory proteins, and clinical outcomes. The analysis covers 1,034 protein targets and focuses on thoracic cancers as well as other solid tumors. Data will come from patients treated as first-line therapy who provide informed consent. The study is sponsored by University Hospitals Coventry and Warwickshire NHS Trust with Coventry University involvement.
Why it matters
Potential benefit: If successful, the findings could help personalize cancer treatment by identifying biomarkers that reflect treatment response or predict toxicity.
How similar studies have gone: Previous work has shown that circulating miRNAs and protein biomarkers can reflect treatment response and toxicity in cancer, but this study builds on that by comparing two distinct treatment paradigms.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients (Age \>18 years) * Histologically/Cytological confirmed solid tumour * Treated with radical RT or concurrent chemo-RT (Cohort 1) OR * Treated with chemo-IO or IO-IO combination (Cohort 2) * First-line treatment * Able to provide informed consent * Willing to comply with study procedures Exclusion Criteria: * Contraindication for RT or chemotherapy (Cohort 1) OR * Contraindication for chemotherapy or IO (Cohort 2) * Use of chemotherapy or immunotherapy in the last 5 years. (Cohort 1) OR * Use of radical RT or chemo-RT within the thorax in the last 5 years. (Cohort 2) * Beyond first-line treatment (second line onwards) * Has more than 1 active cancer requiring treatment * Recent participation in an interventional study * Pregnant or breastfeeding women * On long term cytotoxics or immune-modulators for rheumatoid arthritis or connective tissue disorders or auto-immune disorders * Poor life expectancy, likely less than 6 months * Patients not likely to comply with treatment or the study
Where it's running
-
University Hospitals Coventry & Warwickshire NHS Trust
Coventry, United Kingdom Recruiting
Study contacts
- Study coordinator: Hardip Sandhu, MBA, BSc, MSc, PhD
- Email: ab1682@coventry.ac.uk
- Phone: +442477 659305
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Blood exosomal RNA test to rule out prostate cancer spread to bone
This project will try a blood-based exosomal RNA test to see if it can rule out bone metastasis in people with newly diagnosed, treatment‑naïve prostate cancer scheduled for baseline PSMA PET.
-
Gyrotonic exercise for elders with breast cancer and Behcet disease
We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.
-
PECS II vs SPSIP nerve blocks for pain after mastectomy
This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Compare a new endoscopy-assisted breast-conserving surgery with the usual approach
This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.
-
Different skin care approaches to prevent skin reactions after mastectomy radiation
This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.